Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01076400 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants… | Phase 1 / Phase 2 | terminated | Feb 26, 2010 | Merck Sharp & Dohme LLC | The sponsor permanently suspended new enrollment into the trial and discontinued the study; which… | Safety / toxicity |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free…(CARE) | Phase 3 | withdrawn | Mar 16, 2023 | GenesisCare USA | Bayer withdrew their support. | Other (stated, no rule matched) |
| NCT00176644 | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer | Phase 2 | terminated | Sep 15, 2005 | University of Medicine and Dentistry of New Jersey | Treatment ineffective | Other (stated, no rule matched) |
| NCT00483561 | Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not… | Phase 2 | terminated | Jun 7, 2007 | University of Nebraska | PI left UNMC | Investigator |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated… | Phase 1 / Phase 2 | terminated | Mar 25, 2010 | University of Nebraska | study sponsors withdrew support for the study drug. | Other (stated, no rule matched) |
| NCT05201001 | APX005M in Patients With Recurrent Ovarian Cancer(APX005M) | Phase 2 | withdrawn | Jan 21, 2022 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | IMP provider company (Apexigen) is sold, thus both IMP and grant is terminated | Sponsor / business decision |
| NCT03302156 | PSMA PET and MRI in Gynecological Cancers | Phase 2 | terminated | Oct 4, 2017 | University of Wisconsin, Madison | Slow accrual following suspension per COVID-19 | COVID-19 / pandemic |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic…(CHARTER) | — | terminated | Jun 29, 2022 | Angle plc | Futility (slow enrollment) | Efficacy / futility |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT00499174 | Observation or Radical Treatment in Patients With Prostate Cancer | N/A | terminated | Jul 11, 2007 | NCIC Clinical Trials Group | Not meeting accrual target. | Enrollment / accrual |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | N/A | terminated | Jun 7, 2011 | Albert Einstein College of Medicine | Lack of accrual. PI left the institution | Investigator |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Jan 13, 2020 | Tceleron Therapeutics, Inc. | Based on the safety events and evidence of biologic activity without sustained clinical responses… | Safety / toxicity |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic… | Phase 1 / Phase 2 | terminated | Aug 5, 2022 | Tceleron Therapeutics, Inc. | Study was stopped Sponsor discretion. No patients were dosed. | Other (stated, no rule matched) |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With… | N/A | terminated | Oct 9, 2013 | Albert Einstein College of Medicine | Study terminated due to low accrual. PI left the institution | Investigator |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | Phase 3 | withdrawn | Oct 28, 2021 | State University of New York at Buffalo | no participant enrolled due to lack of interest. | Enrollment / accrual |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler… | N/A | withdrawn | May 9, 2022 | Cooler Heads Care Inc. | Single-site study, site was unable to participate | Other (stated, no rule matched) |
| NCT00786682 | Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | Phase 2 | terminated | Nov 6, 2008 | University of Medicine and Dentistry of New Jersey | Lack of improved efficacy compared to historical controls, competing studies | Efficacy / futility |
| NCT00794339 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer(ACRIN6682) | Phase 2 | terminated | Nov 20, 2008 | American College of Radiology | transfer of funding | Funding |
| NCT01555632 | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients… | N/A | withdrawn | Mar 15, 2012 | University of Nebraska | Other more favorable treatments are now available. | Other (stated, no rule matched) |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal… | Phase 2 | terminated | Aug 26, 2019 | M.D. Anderson Cancer Center | Due to Issues Enrolling Patients | Enrollment / accrual |
| NCT05026502 | A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of…(REACH) | — | terminated | Aug 30, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | Phase 1 | terminated | Oct 5, 2020 | Novo Nordisk A/S | Sponsor Decision | Sponsor / business decision |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A… | N/A | terminated | Aug 31, 2009 | Cantonal Hospital of St. Gallen | poor patient accrual | Enrollment / accrual |
| NCT00651326 | Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate…(DART) | Phase 3 | terminated | Apr 2, 2008 | NCIC Clinical Trials Group | Poor accrual | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT05010759 | Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for… | N/A | terminated | Aug 18, 2021 | MagForce USA | Inadequate enrollment and company changing direction | Enrollment / accrual |
| NCT02341118 | Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and… | — | terminated | Jan 19, 2015 | University Health Network, Toronto | This study did not collect sufficient data for primary endpoint analysis. | Other (stated, no rule matched) |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV… | Phase 3 | terminated | Oct 18, 2022 | Shanghai Bovax Biotechnology Co., Ltd. | Strategic adjustment | Sponsor / business decision |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | withdrawn | Mar 4, 2021 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer… | Phase 1 | terminated | Apr 25, 2019 | AvenCell Europe GmbH | business decision by sponsor | Sponsor / business decision |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | N/A | withdrawn | Mar 1, 2006 | University of New Mexico | not stated | Not stated |
| NCT04163094 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With…(OLIVIA) | Phase 1 | terminated | Nov 14, 2019 | University Medical Center Groningen | Despite the extension of the original recruitment period, the target number of evaluable patients… | Enrollment / accrual |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | Phase 3 | withdrawn | May 6, 2022 | AdventHealth | Study was withdrawn due to lack of funding | Funding |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer…(ITTACC) | Phase 2 | withdrawn | Nov 14, 2022 | Australia New Zealand Gynaecological Oncology Group | BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing… | Drug supply |
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in… | Phase 2 | terminated | Dec 29, 2015 | Swiss Cancer Institute | The decision is based on the fact that with the current follow up of around 10 years, the relevant… | Other (stated, no rule matched) |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | Phase 2 | withdrawn | Aug 9, 2021 | St. Louis University | No participants were recruited and the study was deemed not feasible | Enrollment / accrual |
| NCT00002668 | Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | N/A | terminated | Jan 27, 2003 | Eastern Cooperative Oncology Group | Slow accrual | Enrollment / accrual |
| NCT01133756 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine… | Phase 1 / Phase 2 | terminated | May 31, 2010 | Eisai Inc. | poor accrual | Enrollment / accrual |
| NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer(GTx758) | Phase 2 | terminated | Mar 30, 2011 | GTx | FDA Clinical Hold | Other (stated, no rule matched) |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and… | Phase 1 | withdrawn | Jun 24, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected… | Phase 2 | terminated | Jan 31, 2019 | pharmaand GmbH | Sponsor made a business decision to discontinue the study due to low accrual. | Enrollment / accrual |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate… | Phase 2 | terminated | Aug 6, 2015 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | insufficient clinical response per DSMB | Other (stated, no rule matched) |
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Phase 2 | withdrawn | Aug 12, 2020 | University Health Network, Toronto | 19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot… | Enrollment / accrual |
| NCT05742334 | Evaluating Return to Continence and Potency Following Radical Prostatectomy | N/A | withdrawn | Feb 24, 2023 | Wake Forest University Health Sciences | The sponsor decided to not move forward with this study | Sponsor / business decision |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined…(THRIP) | N/A | terminated | Jun 12, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | outdated, progress in clinical practice. | Other (stated, no rule matched) |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With… | Phase 2 | withdrawn | Oct 10, 2008 | Eastern Cooperative Oncology Group | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Sep 18, 2023source: clinicaltrials